The Narrow-Spectrum HDAC Inhibitor Entinostat Enhances NKG2D Expression Without NK Cell Toxicity, Leading to Enhanced Recognition of Cancer Cells

详细信息    查看全文

• 作者：Shiguo Zhu (1)
  Cecele J. Denman (2)
  Zehra S. Cobanoglu (2)
  Simin Kiany (2)
  Ching C. Lau (3)
  Stephen M. Gottschalk (4)
  Dennis P. M. Hughes (2)
  Eugenie S. Kleinerman (2)
  Dean A. Lee (2) (5)
  
  1. Shanghai University of Traditional Chinese Medicine School of Basic Medical Sciences ; Shanghai ; China
  2. Division of Pediatrics ; The University of Texas MD Anderson Cancer Center ; Houston ; Texas ; USA
  3. Hematology/Oncology Section ; Department of Pediatrics ; Baylor College of Medicine ; Houston ; Texas ; USA
  4. Baylor College of Medicine ; Department of Pediatrics Center for Cell and Gene Therapy ; Texas Children鈥檚 Cancer Center ; Houston ; Texas ; USA
  5. Pediatrics Unit #853 ; University of Texas MD Anderson Cancer Center ; 1515 Holcombe Boulevard ; Houston ; Texas ; 77030-4009 ; USA
  
• 关键词：cancer ; HDAC inhibitor ; natural killer cells ; NKG2D ; NKG2D ligands
• 刊名：Pharmaceutical Research
• 出版年：2015
• 出版时间：March 2015
• 年：2015
• 卷：32
• 期：3
• 页码：779-792
• 全文大小：2,560 KB
• 参考文献：1. Miller JS, Soignier Y, Panoskaltsis-Mortari A, McNearney SA, Yun GH, Fautsch SK, / et al. Successful adoptive transfer and in vivo expansion of human haploidentical NK cells in patients with cancer. Blood. 2005;105:3051鈥?. CrossRef
  2. Cho D, Shook DR, Shimasaki N, Chang YH, Fujisaki H, Campana D. Cytotoxicity of activated natural killer cells against pediatric solid tumors. Clin Cancer Res. 2010;16:3901鈥?. CrossRef
  3. Lanier LL. NK cell recognition. Annu Rev Immunol. 2005;23:225鈥?4. CrossRef
  4. Pende D, Rivera P, Marcenaro S, Chang CC, Biassoni R, Conte R, / et al. Major histocompatibility complex class I-related chain A and UL16-binding protein expression on tumor cell lines of different histotypes: analysis of tumor susceptibility to NKG2D-dependent natural killer cell cytotoxicity. Cancer Res. 2002;62:6178鈥?6.
  5. Sutherland CL, Rabinovich B, Chalupny NJ, Brawand P, Miller R, Cosman D. ULBPs, human ligands of the NKG2D receptor, stimulate tumor immunity with enhancement by IL-15. Blood. 2006;108:1313鈥?. CrossRef
  6. Wu J, Song Y, Bakker AB, Bauer S, Spies T, Lanier LL, / et al. An activating immunoreceptor complex formed by NKG2D and DAP10. Science. 1999;285:730鈥?. CrossRef
  7. Roberts AI, Lee L, Schwarz E, Groh V, Spies T, Ebert EC, / et al. NKG2D receptors induced by IL-15 costimulate CD28-negative effector CTL in the tissue microenvironment. J Immunol. 2001;167:5527鈥?0. CrossRef
  8. Burgess SJ, Marusina AI, Pathmanathan I, Borrego F, Coligan JE. IL-21 down-regulates NKG2D/DAP10 expression on human NK and CD8+ T cells. J Immunol. 2006;176:1490鈥?. CrossRef
  9. Bubenik J. MHC class I down-regulation: tumour escape from immune surveillance? (review). Int J Oncol. 2004;25:487鈥?1.
  10. Mariani E, Tarozzi A, Meneghetti A, Cattini L, Facchini A. Human osteosarcoma cell susceptibility to natural killer cell lysis depends on CD54 and increases after TNF alpha incubation. FEBS letters. 1997;406:83鈥?. CrossRef
  11. Buddingh EP, Schilham MW, Ruslan SE, Berghuis D, Szuhai K, Suurmond J, / et al. Chemotherapy-resistant osteosarcoma is highly susceptible to IL-15-activated allogeneic and autologous NK cells. Cancer Immunol Immunother. 2011;60:575鈥?6. CrossRef
  12. Rohner A, Langenkamp U, Siegler U, Kalberer CP, Wodnar-Filipowicz A. Differentiation-promoting drugs up-regulate NKG2D ligand expression and enhance the susceptibility of acute myeloid leukemia cells to natural killer cell-mediated lysis. Leuk Res. 2007;31:1393鈥?02. CrossRef
  13. Kato N, Tanaka J, Sugita J, Toubai T, Miura Y, Ibata M, / et al. Regulation of the expression of MHC class I-related chain A, B (MICA, MICB) via chromatin remodeling and its impact on the susceptibility of leukemic cells to the cytotoxicity of NKG2D-expressing cells. Leukemia. 2007;21:2103鈥?. CrossRef
  14. Armeanu S, Bitzer M, Lauer UM, Venturelli S, Pathil A, Krusch M, / et al. Natural killer cell-mediated lysis of hepatoma cells via specific induction of NKG2D ligands by the histone deacetylase inhibitor sodium valproate. Cancer Res. 2005;65:6321鈥?. CrossRef
  15. Diermayr S, Himmelreich H, Durovic B, Mathys-Schneeberger A, Siegler U, Langenkamp U, / et al. NKG2D ligand expression in AML increases in response to HDAC inhibitor valproic acid and contributes to allorecognition by NK-cell lines with single KIR-HLA class I specificities. Blood. 2008;111:1428鈥?6. CrossRef
  16. Zhang C, Wang Y, Zhou Z, Zhang J, Tian Z. Sodium butyrate upregulates expression of NKG2D ligand MICA/B in HeLa and HepG2 cell lines and increases their susceptibility to NK lysis. Cancer Immunol Immunother. 2009;58:1275鈥?5. CrossRef
  17. Lundqvist A, Abrams SI, Schrump DS, Alvarez G, Suffredini D, Berg M, / et al. Bortezomib and depsipeptide sensitize tumors to tumor necrosis factor-related apoptosis-inducing ligand: a novel method to potentiate natural killer cell tumor cytotoxicity. Cancer Res. 2006;66:7317鈥?5. CrossRef
  18. Ogbomo H, Michaelis M, Kreuter J, Doerr HW, Cinatl Jr J. Histone deacetylase inhibitors suppress natural killer cell cytolytic activity. FEBS Lett. 2007;581:1317鈥?2. CrossRef
  19. Kelly-Sell MJ, Kim YH, Straus S, Benoit B, Harrison C, Sutherland K, / et al. The histone deacetylase inhibitor, romidepsin, suppresses cellular immune functions of cutaneous T-cell lymphoma patients. Am J Hematol. 2012;87:354鈥?0. CrossRef
  20. Saito A, Yamashita T, Mariko Y, Nosaka Y, Tsuchiya K, Ando T, / et al. A synthetic inhibitor of histone deacetylase, MS-27-275, with marked in vivo antitumor activity against human tumors. Proc Natl Acad Sci U S A. 1999;96:4592鈥?. CrossRef
  21. Jaboin J, Wild J, Hamidi H, Khanna C, Kim CJ, Robey R, / et al. MS-27-275, an inhibitor of histone deacetylase, has marked in vitro and in vivo antitumor activity against pediatric solid tumors. Cancer Res. 2002;62:6108鈥?5.
  22. Bridle BW, Chen L, Lemay CG, Diallo JS, Pol J, Nguyen A, / et al. HDAC inhibition suppresses primary immune responses, enhances secondary immune responses, and abrogates autoimmunity during tumor immunotherapy. Mol Ther. 2013;21:887鈥?4. CrossRef
  23. Shen L, Ciesielski M, Ramakrishnan S, Miles KM, Ellis L, Sotomayor P, / et al. Class I histone deacetylase inhibitor entinostat suppresses regulatory T cells and enhances immunotherapies in renal and prostate cancer models. PLoS One. 2012;7:e30815. CrossRef
  24. Berghuis D, Schilham MW, Vos HI, Santos SJ, Kloess S, Buddingh EP, / et al. Histone deacetylase inhibitors enhance expression of NKG2D ligands in Ewing sarcoma and sensitize for natural killer cell-mediated cytolysis. Clin Sarcoma Res. 2012;2:8. CrossRef
  25. Hughes DP, Thomas DG, Giordano TJ, Baker LH, McDonagh KT. Cell surface expression of epidermal growth factor receptor and Her-2 with nuclear expression of Her-4 in primary osteosarcoma. Cancer Res. 2004;64:2047鈥?3. CrossRef
  26. Bollard CM, Rossig C, Calonge MJ, Huls MH, Wagner HJ, Massague J, / et al. Adapting a transforming growth factor beta-related tumor protection strategy to enhance antitumor immunity. Blood. 2002;99:3179鈥?7. CrossRef
  27. Warrenand HS, Rana PM. An economical adaptation of the RosetteSep procedure for NK cell enrichment from whole blood, and its use with liquid nitrogen stored peripheral blood mononuclear cells. J Immunol Methods. 2003;280:135鈥?. CrossRef
  28. Denman CJ, Senyukov VV, Somanchi SS, Phatarpekar PV, Kopp LM, Johnson JL, / et al. Membrane-bound IL-21 promotes sustained ex vivo proliferation of human natural killer cells. PLoS One. 2012;7:e30264. CrossRef
  29. Gore L, Rothenberg ML, O鈥橞ryant CL, Schultz MK, Sandler AB, Coffin D, / et al. A phase I and pharmacokinetic study of the oral histone deacetylase inhibitor, MS-275, in patients with refractory solid tumors and lymphomas. Clin Cancer Res. 2008;14:4517鈥?5. CrossRef
  30. Man TK, Chintagumpala M, Visvanathan J, Shen J, Perlaky L, Hicks J, / et al. Expression profiles of osteosarcoma that can predict response to chemotherapy. Cancer Res. 2005;65:8142鈥?0. CrossRef
  31. Kato Y, Yoshimura K, Shin T, Verheul H, Hammers H, Sanni TB, / et al. Synergistic in vivo antitumor effect of the histone deacetylase inhibitor MS-275 in combination with interleukin 2 in a murine model of renal cell carcinoma. Clin Cancer Res. 2007;13:4538鈥?6. CrossRef
  32. Schmudde M, Braun A, Pende D, Sonnemann J, Klier U, Beck JF, / et al. Histone deacetylase inhibitors sensitize tumour cells for cytotoxic effects of natural killer cells. Cancer Lett. 2008;272:110鈥?1. CrossRef
  33. Khan N, Jeffers M, Kumar S, Hackett C, Boldog F, Khramtsov N, / et al. Determination of the class and isoform selectivity of small-molecule histone deacetylase inhibitors. The Biochemical Journal. 2008;409:581鈥?. CrossRef
  34. Ryan QC, Headlee D, Acharya M, Sparreboom A, Trepel JB, Ye J, / et al. Phase I and pharmacokinetic study of MS-275, a histone deacetylase inhibitor, in patients with advanced and refractory solid tumors or lymphoma. J Clin Oncol. 2005;23:3912鈥?2. CrossRef
  35. Bagatell R, Gore L, Egorin MJ, Ho R, Heller G, Boucher N, / et al. Phase I pharmacokinetic and pharmacodynamic study of 17-N-allylamino-17-demethoxygeldanamycin in pediatric patients with recurrent or refractory solid tumors: a pediatric oncology experimental therapeutics investigators consortium study. Clin Cancer Res. 2007;13:1783鈥?. CrossRef
  36. Epling-Burnette PK, Bai F, Painter JS, Rollison DE, Salih HR, Krusch M, / et al. Reduced natural killer (NK) function associated with high-risk myelodysplastic syndrome (MDS) and reduced expression of activating NK receptors. Blood. 2007;109:4816鈥?4. CrossRef
  37. Varker KA, Terrell CE, Welt M, Suleiman S, Thornton L, Andersen BL, / et al. Impaired natural killer cell lysis in breast cancer patients with high levels of psychological stress is associated with altered expression of killer immunoglobin-like receptors. J Surg Res. 2007;139:36鈥?4. CrossRef
  38. Sconocchia G, Lau M, Provenzano M, Rezvani K, Wongsena W, Fujiwara H, / et al. The antileukemia effect of HLA-matched NK and NK-T cells in chronic myelogenous leukemia involves NKG2D-target-cell interactions. Blood. 2005;106:3666鈥?2. CrossRef
  39. Rao-Bindal K, Zhou Z, Kleinerman ES. MS-275 sensitizes osteosarcoma cells to Fas ligand-induced cell death by increasing the localization of Fas in membrane lipid rafts. Cell Death Dis. 2012;3:e369. CrossRef
  40. Rao-Bindal K, Koshkina NV, Stewart J, Kleinerman ES. The histone deacetylase inhibitor, MS-275 (Entinostat), downregulates c-FLIP, sensitizes osteosarcoma cells to FasL, and induces the regression of osteosarcoma lung metastases. Curr Cancer Drug Targets 2013;13:411鈥?2.
  
• 刊物类别：Biomedical and Life Sciences
• 刊物主题：Biomedicine
  Pharmacology and Toxicology
  Pharmacy
  Biochemistry
  Medical Law
  Biomedical Engineering
  
• 出版者：Springer Netherlands
• ISSN：1573-904X

文摘